Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
about
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert GroupGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursSmall bowel neuroendocrine tumors: From pathophysiology to clinical approachNeuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewGastroenteropancreatic high-grade neuroendocrine carcinomaManagement of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphologyNeuroendocrine tumors of the gastro-entero-pancreatic systemNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Atypical presentation of carcinoid tumor with unresolved right shoulder pain: a case report.Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case studyPoorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaRelationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Advances in diagnosis and therapy of neuroendocrine tumors.New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Update on the treatment of neuroendocrine tumors.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.Chemotherapy for gastro-enteropancreatic endocrine tumours.Non-transitional cell bladder carcinomas.Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues OncologuesDoes the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?Poorly Differentiated Neuroendocrine Tumor of the Rectum Coexistent with Giant Rectal Villous Adenoma Presenting as McKittrick-Wheelock SyndromeFirst-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site.Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.
P2860
Q24674315-DE507339-6283-4D09-B25E-4B10F847C95EQ24685837-E39B0074-EFA0-4D01-AF0F-315B966689A3Q26766650-CDA455EE-D448-4C3B-841A-1B57EA52A92FQ26768483-52A57D54-A463-4828-806F-3588D240F4D1Q26998392-04137168-71CC-45B8-9C24-F5E68F903CB1Q28078501-4EAF2A73-C3B6-432C-A905-5820075FCE58Q28294432-E46AD5B6-6501-447B-A441-52B266689B58Q30238552-55359426-F133-49CD-ACC0-2E43E28F35A6Q30249051-3483D369-C236-4817-ACB6-ACC76CA4680BQ33388860-DE3852F5-45F2-4B7B-A5A3-96940EBD746EQ33394763-66FF2EE5-82B1-46EE-887C-A5153B787195Q33648996-D83E42E9-6D85-4DD0-82D3-FF0C934B66AEQ33653772-5C633F4B-D389-4CA0-8AD7-C2438ADC58C2Q33783119-9706A6BD-E672-4945-8CC1-108F1FD8DCDFQ33957571-99A71ECA-5E63-4E30-B9FF-A6A07A88512AQ34063746-077D54B9-879B-4476-8252-B42821869300Q34283282-62FC1B89-BF63-4A06-8A9D-A686DD8502AEQ34414279-60FA5962-31CB-4ECA-ABF0-40AAF4DA0417Q34446086-D9D04428-D757-44C0-954E-149088CAB001Q34484273-CE2263F9-2CC0-445B-8B58-0D722D83F7FCQ34495609-90D462DD-F893-48BB-9269-61DBE8CE7651Q34564262-E8BC519C-FA8F-4574-BBFF-99D08ACF4A3DQ34734203-62B5EF09-A736-4D6D-8FF1-19355B642588Q35097493-F3E709DB-9B4F-4722-BBA9-15BF6321DFC3Q35178055-F40B8E93-22B7-4F70-84C5-21EF639A8180Q35371197-3A28E873-E0F0-4650-A889-FF60A8EB1DFDQ35576166-F261FCC9-4007-4A7F-8BE7-E862661491FDQ35669138-73C4B45E-216B-46F4-883C-B0D56B767395Q35713556-2DE5A041-417D-4FF9-B2AA-5ABEE2FC2799Q35760798-BB2FEC13-3315-4BEF-AA99-1BF8571E4A5BQ35843079-4C8D8EC2-DC2C-4B18-8436-62557579F945Q35907055-FDA91424-F71F-4795-9362-A734940B769BQ35915027-0332F08A-B78C-4B3B-8475-78A036184CCDQ36037516-A7EC7A56-6EBD-4FDA-839F-EB2FAA39ECD2Q36206880-A8E86CA4-E075-4B30-B709-1945DED3B8DAQ36300517-FA0B49A5-9DDB-4F60-8190-9F0C11D06E39Q36349306-CB970864-316F-4E83-9D64-0087F0D26478Q36352317-9762373D-8465-46B6-AD86-46BA66F2DDEFQ36537008-218AA495-FCF5-458E-814A-22D30244A5CAQ36610457-468C69FB-9C36-4B9C-A01C-211932F0E3FA
P2860
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@ast
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@en
type
label
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@ast
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@en
prefLabel
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@ast
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@en
P2093
P2860
P356
P1476
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
@en
P2093
Aparicio T
Duvillard P
Sabourin JC
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690325
P407
P577
1999-12-01T00:00:00Z
P5875
P6179
1033288252